Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma
© 2021 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles..
Minimally-invasive tools to assess tumour presence and burden may improve clinical management. FDG-PET (metabolic) imaging is the current gold standard for interim response assessment in patients with classical Hodgkin Lymphoma (cHL), but this technique cannot be repeated frequently. Here we show that microRNAs (miRNA) associated with tumour-secreted extracellular vesicles (EVs) in the circulation of cHL patients may improve response assessment. Small RNA sequencing and qRT-PCR reveal that the relative abundance of cHL-expressed miRNAs, miR-127-3p, miR-155-5p, miR-21-5p, miR-24-3p and let-7a-5p is up to hundred-fold increased in plasma EVs of cHL patients pre-treatment when compared to complete metabolic responders (CMR). Notably, in partial responders (PR) or treatment-refractory cases (n = 10) the EV-miRNA levels remain elevated. In comparison, tumour specific copy number variations (CNV) were detected in cell-free DNA of 8 out of 10 newly diagnosed cHL patients but not in patients with PR. Combining EV-miR-127-3p and/or EV-let-7a-5p levels, with serum TARC (a validated protein cHL biomarker), increases the accuracy for predicting PET-status (n = 129) to an area under the curve of 0.93 (CI: 0.87-0.99), 93.5% sensitivity, 83.8/85.0% specificity and a negative predictive value of 96%. Thus the level of tumour-associated miRNAs in plasma EVs is predictive of metabolic tumour activity in cHL patients. Our findings suggest that plasma EV-miRNA are useful for detection of small residual lesions and may be applied as serial response prediction tool.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Journal of extracellular vesicles - 10(2021), 9 vom: 15. Juli, Seite e12121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Drees, Esther E E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.02.2022 Date Revised 02.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jev2.12121 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328403776 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328403776 | ||
| 003 | DE-627 | ||
| 005 | 20240402234718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jev2.12121 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1360.xml |
| 035 | |a (DE-627)NLM328403776 | ||
| 035 | |a (NLM)34295456 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Drees, Esther E E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin Lymphoma |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.02.2022 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles. | ||
| 520 | |a Minimally-invasive tools to assess tumour presence and burden may improve clinical management. FDG-PET (metabolic) imaging is the current gold standard for interim response assessment in patients with classical Hodgkin Lymphoma (cHL), but this technique cannot be repeated frequently. Here we show that microRNAs (miRNA) associated with tumour-secreted extracellular vesicles (EVs) in the circulation of cHL patients may improve response assessment. Small RNA sequencing and qRT-PCR reveal that the relative abundance of cHL-expressed miRNAs, miR-127-3p, miR-155-5p, miR-21-5p, miR-24-3p and let-7a-5p is up to hundred-fold increased in plasma EVs of cHL patients pre-treatment when compared to complete metabolic responders (CMR). Notably, in partial responders (PR) or treatment-refractory cases (n = 10) the EV-miRNA levels remain elevated. In comparison, tumour specific copy number variations (CNV) were detected in cell-free DNA of 8 out of 10 newly diagnosed cHL patients but not in patients with PR. Combining EV-miR-127-3p and/or EV-let-7a-5p levels, with serum TARC (a validated protein cHL biomarker), increases the accuracy for predicting PET-status (n = 129) to an area under the curve of 0.93 (CI: 0.87-0.99), 93.5% sensitivity, 83.8/85.0% specificity and a negative predictive value of 96%. Thus the level of tumour-associated miRNAs in plasma EVs is predictive of metabolic tumour activity in cHL patients. Our findings suggest that plasma EV-miRNA are useful for detection of small residual lesions and may be applied as serial response prediction tool | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Hodgkin lymphoma | |
| 650 | 4 | |a blood | |
| 650 | 4 | |a extracellular vesicles | |
| 650 | 4 | |a liquid biopsy | |
| 650 | 4 | |a miRNA | |
| 650 | 4 | |a response monitoring | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a Fluorodeoxyglucose F18 |2 NLM | |
| 650 | 7 | |a 0Z5B2CJX4D |2 NLM | |
| 700 | 1 | |a Roemer, Margaretha G M |e verfasserin |4 aut | |
| 700 | 1 | |a Groenewegen, Nils J |e verfasserin |4 aut | |
| 700 | 1 | |a Perez-Boza, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a van Eijndhoven, Monique A J |e verfasserin |4 aut | |
| 700 | 1 | |a Prins, Leah I |e verfasserin |4 aut | |
| 700 | 1 | |a Verkuijlen, Sandra A W M |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Xuan-Mai |e verfasserin |4 aut | |
| 700 | 1 | |a Driessen, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Zwezerijnen, G J C |e verfasserin |4 aut | |
| 700 | 1 | |a Stathi, Phylicia |e verfasserin |4 aut | |
| 700 | 1 | |a Mol, Kevin |e verfasserin |4 aut | |
| 700 | 1 | |a Karregat, Joey J J P |e verfasserin |4 aut | |
| 700 | 1 | |a Kalantidou, Aikaterini |e verfasserin |4 aut | |
| 700 | 1 | |a Vallés-Martí, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Molenaar, T J |e verfasserin |4 aut | |
| 700 | 1 | |a Aparicio-Puerta, Ernesto |e verfasserin |4 aut | |
| 700 | 1 | |a van Dijk, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Ylstra, Bauke |e verfasserin |4 aut | |
| 700 | 1 | |a Groothuis-Oudshoorn, Catharina G M |e verfasserin |4 aut | |
| 700 | 1 | |a Hackenberg, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a de Jong, Daphne |e verfasserin |4 aut | |
| 700 | 1 | |a Zijlstra, Josée M |e verfasserin |4 aut | |
| 700 | 1 | |a Pegtel, D Michiel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of extracellular vesicles |d 2012 |g 10(2021), 9 vom: 15. Juli, Seite e12121 |w (DE-627)NLM230631029 |x 2001-3078 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:9 |g day:15 |g month:07 |g pages:e12121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jev2.12121 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 9 |b 15 |c 07 |h e12121 | ||